Then, a signature of nine DRICGs (CD276, HLA-E, CD80, CD86, LAG3, PVR, PDCD1LG2, TIGIT and TNFRSF4) was constructed that was associated with the survival rates of ccRCC. This evidence concerns the gene CD276 and nonpapillary renal cell carcinoma.